Compare ASGN & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASGN | AGIO |
|---|---|---|
| Founded | 1985 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 1992 | 2013 |
| Metric | ASGN | AGIO |
|---|---|---|
| Price | $51.74 | $27.41 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $50.20 | $36.25 |
| AVG Volume (30 Days) | 477.4K | ★ 943.3K |
| Earning Date | 02-04-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.96 | N/A |
| Revenue | ★ $3,985,300,000.00 | $44,791,000.00 |
| Revenue This Year | N/A | $27.83 |
| Revenue Next Year | $0.57 | $133.46 |
| P/E Ratio | $17.63 | ★ N/A |
| Revenue Growth | N/A | ★ 36.26 |
| 52 Week Low | $39.25 | $22.24 |
| 52 Week High | $93.95 | $46.00 |
| Indicator | ASGN | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 60.16 | 45.61 |
| Support Level | $48.26 | $26.25 |
| Resistance Level | $51.81 | $29.93 |
| Average True Range (ATR) | 1.74 | 1.13 |
| MACD | -0.04 | 0.09 |
| Stochastic Oscillator | 83.33 | 31.79 |
ASGN Inc is a provider of information technology (IT) services and professional solutions, including technology, creative, and digital, across the commercial and government sectors. It operates through two segments, Commercial and Federal Government. The Commercial Segment, which generates the majority of the revenue, provides consulting, creative digital marketing, and permanent placement services to Fortune 1000 clients and mid-market companies. The Federal Government Segment provides mission-critical solutions to the Department of Defense, intelligence agencies, and civilian agencies.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.